This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics' Upcoming FDA Worries

SEATTLE ( TheStreet) -- Can Cell Therapeutics (CTIC - Get Report) and its lymphoma drug pixantrone withstand the withering scrutiny of U.S. drug regulators?

The answer comes Feb. 10, when Cell Therapeutics travels to suburban Washington D.C. to make its case for pixantrone's approval to a panel of cancer experts convened by the U.S Food and Drug Administration.

The FDA's advisory panel will be reviewing data from a phase III study of pixantrone in patients with advanced, aggressive non-Hodgkin's lymphoma. The "EXTEND" study was conducted under a Special Protocol Assessment from the FDA, and the results, as presented by Cell Therapeutics to date, appear to be positive.

Of course, clinical data from "positive" phase III trials always looks great when pitched by the company developing the drug. The truth about a drug's efficacy is often something different and far less robust, especially after FDA reviewers finish picking apart the data line by line.

If the pixantrone data closet does have skeletons -- and let's face it, no drug skates through an FDA review unscathed -- here's where they might be found:

1. Missing patients?

Cell Therapeutics designed the pixantrone EXTEND study in 2003 - 2004 with the intention of enrolling 320 patients. In March 2008, however, Cell Therapeutics announced that it halted enrollment at 140 patients.

Will FDA accept the results from this study, given that only 40% of the planned patients actually enrolled? How does the drastically smaller number of patients effect the statistical powering of the study? And given the fact that the study is open label -- meaning doctors and patients know who's getting pixantrone and who's getting a comparator drug -- what amended rules were put in place to say that 140 patients were sufficient to prove pixantrone's efficacy?
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.24 5.51%
AAPL $118.03 -0.71%
FB $105.52 -0.21%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs